Accuray Incorporated (NASDAQ:ARAY) Sees Large Increase in Short Interest

Accuray Incorporated (NASDAQ:ARAY) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 4,500,000 shares, a growth of 11.7% from the January 15th total of 4,030,000 shares. Based on an average trading volume of 740,500 shares, the short-interest ratio is presently 6.1 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its holdings in Accuray by 0.9% in the 4th quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider’s stock valued at $1,603,000 after purchasing an additional 7,399 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in Accuray in the 4th quarter worth $66,000. MetLife Investment Management LLC grew its holdings in Accuray by 38.3% in the 4th quarter. MetLife Investment Management LLC now owns 48,234 shares of the medical equipment provider’s stock worth $96,000 after acquiring an additional 13,370 shares during the last quarter. Gabelli Funds LLC grew its holdings in Accuray by 12.5% in the 4th quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock worth $89,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Accuray in the 4th quarter worth $300,000. 64.08% of the stock is owned by institutional investors.

Accuray Price Performance

Shares of Accuray stock traded down $0.05 during trading on Friday, hitting $2.23. The company’s stock had a trading volume of 547,852 shares, compared to its average volume of 769,263. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.87 and a current ratio of 1.62. Accuray has a 52 week low of $1.40 and a 52 week high of $2.95. The stock has a 50-day moving average price of $2.14 and a two-hundred day moving average price of $1.99.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Equities analysts anticipate that Accuray will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Accuray from a “hold” rating to a “buy” rating in a report on Monday, February 10th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.